Abstract:Objective:To explore the clinical characteristics of adult patients with fulminant type 1 diabetes mellitus (FT1DM), a specific subtype of type 1 diabetes mellitus (T1DM). Methods:We collected the clinical data of patients who were admitted to West China Hospital, Sichuan University in 2010-2019 for FT1DM and type 1 diabetes mellitus (T1DM) presenting with diabetic ketoacidosis (DKA) at the onset. In addition, all the FT1DM patients were followed up. Results:A total of 70 patients presenting with DKA at the onset of T1DM were admitted to and received treatment at West China Hospital in 2010-2019. Among them, 17 (24.3%) had FT1DM and 53 did not. The mean ages of the FT1DM patients and the non-FT1DM patients were (33.2±12.8) years and (27.5±11.2) years, and the mean body mass indices were (22.6±2.9) kg/m 2 and (19.2±2.9) kg/m 2, respectively. A total of 14 FT1DM cases had symptoms of upper respiratory tract infection or acute gastroenteritis before the onset of the disease and 4 cases were related to pregnancy. The median time from the onset of the disease to the first diagnosis of DKA of the FT1DM group (median [P 25-P 75]: 2 [1-4] days, P<0.001) was significantly shorter than that of the non-FT1DM group (median [P 25-P 75]: 30 [17-78] days). The mean maximum blood glucose levels at the time of the first visit to the doctor of the FT1DM patients ([39.9±11.4] mmol/L, P<0.001) were significantly higher than that of the non-FT1DM patients ([28.9±9.2] mmol/L), but the HbA1c (6.6%±0.6%, P<0.001) and glycosylated serum albumin (GA) (21.4%±3.0%, P=0.001) levels of the FT1DM patients were significantly lower than those of the non-FT1DM group (HbA1c: 12.8%±2.7%; GA: 44.8%±15.0%). The median serum amylase in the FT1DM group was significantly higher than that in the non-FT1DM group (101 [54-336] IU/L vs. 54 [42-166] IU/L, P=0.045) and the median serum lipase in the FT1DM group showed a trend of being higher than that in the T1DM group (81 [57-154] IU/L vs. 46 [28-195] IU/L, P=0.051). 8.7% of the non-FT1DM patients tested positive for anti-glutamic acid decarboxylase antibody (GAD-Ab), while the FT1DM patients all tested negative. At the time of discharge, the mean daily insulin dose of the FT1DM patients was (0.67±0.22) IU/kg, which was not significantly different from that of the non-FT1DM group ([0.74±0.29] IU/kg, P=0.349). After about 6.5 years of follow-up, the mean daily insulin dose of the FT1DM patients was (0.73±0.19) IU/kg, which was similar to the insulin dosage on discharge ( P=0.409). Conclusion:Compared with the non-FT1DM patients presenting with DKA at the onset, FT1DM patients have fewer typical diabetic symptoms, lower fasting C-peptide levels, higher serum amylase levels, and increased incidence of vomiting or other symptoms of gastrointestinal infections, and are more likely to be misdiagnosed. Therefore, it is very important for clinicians to correctly identify FT1DM as early as possible and administer early and long-term insulin replacement therapy.

Fulminant Type 1 Diabetes: A Comprehensive Review of an Autoimmune Condition

The Feature, Diagnosis, and Treatment of Fulminant Type 1 Diabetes

Approach to the patient with fulminant type 1 diabetes

Fulminant Type 1 Diabetes Mellitus Exhibits Distinct Clinical and Autoimmunity Features from Classical Type 1 Diabetes Mellitus in Chinese

Fulminant Type 1 Diabetes in China： a Case Report and Review of the Literature

[Immunological Features of Fulminant Type 1 Diabetes].

Fulminant Type 1 Diabetes:The Clinical Features and Treatment Strategy

[Fulminant type 1 diabetes mellitus with acute pancreatitis: A case report and literature review]

Prevalence and clinical features of fulminant type 1 diabetes

Fulminant type 1 diabetes, an underrecognized and unique subtype of type 1 diabetes: A case series from Singapore

[Clinical Analysis of 17 Adult Patients With Fulminant Type 1 Diabetes Mellitus].

Integrative Analyses of Genes Associated with Fulminant Type 1 Diabetes

Fulminant type 1 diabetes: A distinct subtype of type 1 diabetes mellitus.

Clinical Characteristics of Fulminant Type 1 Diabetes Compared with Typical Type 1 Diabetes: One-Year Follow-Up Study from the Guangdong T1DM Translational Medicine Study

Two cases of conventional fulminant type 1 diabetes: following the depletion process of endogenous insulin secretion and literature review

Serum Metabolic Signatures of Fulminant Type 1 Diabetes.

Classic Type 1 Diabetes Mellitus and Fulminant Type 1 Diabetes Mellitus: Similarity and Discrepancy of Immunological Characteristics and Cytokine Profile.

Fulminant Type 1 Diabetes: A Collaborative Clinical Cases Investigation in China

Type 1 Diabetes: Etiology, Immunology, and Therapeutic Strategies

Advances in the Cellular Immunological Pathogenesis of Type 1 Diabetes.

Autoimmune islet destruction in spontaneous type 1 diabetes is not beta-cell exclusive